Taiwan nears hepatitis C elimination with WHO Gold Tier recognition bid

Taiwan has made major progress in tackling hepatitis C, meeting strict global health targets. The country has submitted its latest elimination report to the World Health Organization for official recognition. Hepatitis C remains a global issue, affecting 58 million people with no vaccine available yet. The WHO aims to end viral hepatitis as a public health threat by 2030. Taiwan's efforts have already led to a drop in liver cancer cases and deaths linked to the disease. Strict measures include full screening of donated blood and safe injection practices across all medical facilities.

Taiwan has focused on high-risk groups and those struggling to access care. Over 90% of people with chronic hepatitis C have been diagnosed, and nearly 93% of them have received treatment. Direct-acting antiviral (DAA) therapies, taken for 8-12 weeks, now offer a cure for the virus. To reduce harm, the country distributes more than 150 clean syringes per person who injects drugs. These combined strategies have helped Taiwan reach the WHO's Gold Tier targets for hepatitis C elimination.

Taiwan's success in screening, treatment, and harm reduction has set a benchmark in the fight against hepatitis C. The WHO will now review its elimination report under the Gold Tier framework. If validated, this achievement could guide other nations working toward the 2030 global elimination goal.